Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

inspire medical systems inc - INSP

INSP

Close Chg Chg %
95.39 -1.65 -1.73%

Closed Market

93.74

-1.65 (1.73%)

Volume: 1.15M

Last Updated:

Dec 29, 2025, 3:59 PM EDT

Trade Now

Company Overview: inspire medical systems inc - INSP

INSP Key Data

Open

$96.52

 Day Range

93.32 - 97.00

52 Week Range

70.84 - 215.85

 Market Cap

$2.77B

Shares Outstanding

29.06M

 Public Float

27.76M

Beta

0.70

 Rev. Per Employee

N/A

P/E Ratio

65.48

 EPS

$1.50

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

2.01M

  

INSP Performance

1 Week
 
 0.00%
 
1 Month
 
 -23.26%
 
3 Months
 
 24.67%
 
1 Year
 
 -49.35%
 
5 Years
 
 -49.24%
 

INSP Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 18
Full Ratings ➔

About inspire medical systems inc - INSP

Inspire Medical Systems, Inc. is a medical technology company, which focuses on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. The firm offers inspire therapy, which consists of a remote control and implantable components that includes pressure sensing lead, a neurostimulator, and a stimulation lead. It operates through the United States and All Other Countries geographical segments. The company was founded by Timothy P. Herbert in November 2007 and is headquartered in Golden Valley, MN.

INSP At a Glance

Inspire Medical Systems, Inc.
5500 Wayzata Boulevard
Golden Valley, Minnesota 55416
Phone 1-844-672-4357 Revenue 802.80M
Industry Medical Specialties Net Income 53.51M
Sector Health Technology 2024 Sales Growth 28.49%
Fiscal Year-end 12 / 2025 Employees 1,246
View SEC Filings

INSP Valuation

P/E Current 65.48
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 105.817
Price to Sales Ratio 7.053
Price to Book Ratio 7.994
Price to Cash Flow Ratio 43.47
Enterprise Value to EBITDA 123.106
Enterprise Value to Sales 6.538
Total Debt to Enterprise Value 0.006

INSP Efficiency

Revenue/Employee 644,304.976
Income Per Employee 42,944.623
Receivables Turnover 8.626
Total Asset Turnover 1.081

INSP Liquidity

Current Ratio 7.128
Quick Ratio 6.222
Cash Ratio 5.034

INSP Profitability

Gross Margin 84.68
Operating Margin 4.495
Pretax Margin 7.281
Net Margin 6.665
Return on Assets 7.206
Return on Equity 8.479
Return on Total Capital 7.416
Return on Invested Capital 8.125

INSP Capital Structure

Total Debt to Total Equity 4.61
Total Debt to Total Capital 4.407
Total Debt to Total Assets 3.933
Long-Term Debt to Equity 4.355
Long-Term Debt to Total Capital 4.163
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Inspire Medical Systems Inc - INSP

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
233.39M 407.86M 624.80M 802.80M
Sales Growth
+102.28% +74.75% +53.19% +28.49%
Cost of Goods Sold (COGS) incl D&A
33.28M 66.11M 96.58M 122.99M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.99M 2.90M 2.85M 6.55M
Depreciation
1.99M 2.90M 2.85M 6.55M
Amortization of Intangibles
- - - -
-
COGS Growth
+88.84% +98.67% +46.07% +27.35%
Gross Income
200.12M 341.74M 528.22M 679.82M
Gross Income Growth
+104.70% +70.77% +54.57% +28.70%
Gross Profit Margin
+85.74% +83.79% +84.54% +84.68%
2021 2022 2023 2024 5-year trend
SG&A Expense
239.97M 389.33M 568.49M 643.74M
Research & Development
37.35M 68.64M 116.54M 114.13M
Other SG&A
202.62M 320.69M 451.96M 529.61M
SGA Growth
+55.86% +62.25% +46.02% +13.24%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(39.85M) (47.59M) (40.27M) 36.08M
Non Operating Income/Expense
8.00K 5.00M 20.36M 22.39M
Non-Operating Interest Income
125.00K 5.05M 20.56M 23.25M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 2.13M 1.68M 22.00K
Interest Expense Growth
- +0.52% -21.19% -100.00%
Gross Interest Expense
- 2.13M 1.68M 22.00K
Interest Capitalized
- - - -
-
Pretax Income
(41.97M) (44.27M) (19.91M) 58.45M
Pretax Income Growth
+26.48% -5.48% +55.03% +393.65%
Pretax Margin
-17.98% -10.85% -3.19% +7.28%
Income Tax
72.00K 613.00K 1.25M 4.94M
Income Tax - Current - Domestic
23.00K 342.00K 644.00K 4.10M
Income Tax - Current - Foreign
49.00K 271.00K 603.00K 854.00K
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - (13.00K)
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(42.04M) (44.88M) (21.15M) 53.51M
Minority Interest Expense
- - - -
-
Net Income
(42.04M) (44.88M) (21.15M) 53.51M
Net Income Growth
+26.50% -6.75% +52.87% +352.96%
Net Margin Growth
-18.01% -11.00% -3.39% +6.67%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(42.04M) (44.88M) (21.15M) 53.51M
Preferred Dividends
- - - -
-
Net Income Available to Common
(42.04M) (44.88M) (21.15M) 53.51M
EPS (Basic)
-1.5421 -1.5988 -0.7219 1.7978
EPS (Basic) Growth
+29.71% -3.68% +54.85% +349.04%
Basic Shares Outstanding
27.26M 28.07M 29.30M 29.76M
EPS (Diluted)
-1.5421 -1.5988 -0.7219 1.7519
EPS (Diluted) Growth
+29.71% -3.68% +54.85% +342.68%
Diluted Shares Outstanding
27.26M 28.07M 29.30M 30.54M
EBITDA
(37.86M) (44.69M) (37.42M) 42.63M
EBITDA Growth
+30.40% -18.05% +16.26% +213.92%
EBITDA Margin
-16.22% -10.96% -5.99% +5.31%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 142.647
Number of Ratings 18 Current Quarters Estimate 0.675
FY Report Date 12 / 2025 Current Year's Estimate 1.603
Last Quarter’s Earnings 0.38 Median PE on CY Estimate N/A
Year Ago Earnings 1.75 Next Fiscal Year Estimate 1.721
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 16 14 12 18
Mean Estimate 0.67 0.08 1.60 1.72
High Estimates 0.77 0.41 1.65 2.31
Low Estimate 0.61 -0.32 1.54 1.31
Coefficient of Variance 6.61 292.16 2.43 15.31

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 11 11 8
OVERWEIGHT 1 1 2
HOLD 6 6 10
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Inspire Medical Systems Inc - INSP

Date Name Shares Transaction Value
Dec 5, 2025 Shawn T. McCormick Director 24,846 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $139 per share 3,453,594.00
Mar 6, 2025 John C. Rondoni Chief Technology Officer 15,500 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $185.6 per share 2,876,800.00
Mar 6, 2025 Randall A. Ban See Remarks 7,259 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $187.08 per share 1,358,013.72
Mar 6, 2025 Randall A. Ban See Remarks 7,737 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $186.2 per share 1,440,629.40
Mar 6, 2025 Randall A. Ban See Remarks 8,970 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $185.37 per share 1,662,768.90
Feb 26, 2025 Richard John Buchholz Chief Financial Officer 36,126 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $186.45 per share 6,735,692.70
Feb 26, 2025 John C. Rondoni Chief Technology Officer 17,787 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $186.45 per share 3,316,386.15
Feb 26, 2025 Timothy P. Herbert CEO and President; Director 35,149 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $186.45 per share 6,553,531.05
Feb 26, 2025 Timothy P. Herbert CEO and President; Director 43,422 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 26, 2025 Bryan K. Phillips See Remarks 15,442 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 26, 2025 Richard John Buchholz Chief Financial Officer 38,326 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 26, 2025 Richard John Buchholz Chief Financial Officer 1,475 Bona fide gift 0.00
Feb 26, 2025 Richard John Buchholz Chief Financial Officer 1,475 Bona fide gift 0.00
Feb 26, 2025 Richard John Buchholz Chief Financial Officer 1,475 Bona fide gift 0.00
Feb 26, 2025 Richard John Buchholz Chief Financial Officer 1,475 Bona fide gift 0.00
Feb 26, 2025 Richard John Buchholz Chief Financial Officer 32,174 Bona fide gift 0.00
Feb 26, 2025 Bryan K. Phillips See Remarks 13,236 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $186.45 per share 2,467,852.20

Inspire Medical Systems Inc in the News